1. What Happened? – Fidelity Reduces Stake in Daehan New Pharm from 8.5% to 8.17%

On July 24, 2025, Fidelity sold 1,714 shares of Daehan New Pharm, lowering its stake from 8.5% to 8.17%. The official reason given was ‘Change report due to the addition of an operating fund,’ and the purpose of holding was stated as ‘simple investment.’

2. Why Did This Happen? – Likely Portfolio Adjustment

This stake change by Fidelity is not a significant decrease and is likely interpreted as a portfolio adjustment due to the addition of an operating fund. Therefore, it is unlikely that this sale is a negative signal about Daehan New Pharm’s fundamentals.

3. Daehan New Pharm’s Current Situation: Solid Fundamentals, but Continuous Growth Efforts Needed

  • Positive Factors

    • Increased sales and profitability in Q3 2025 (Sales: KRW 49.8 billion, Operating profit: KRW 9.2 billion, Net profit: KRW 7.6 billion)
    • Cost reduction due to investment in production facilities
    • Maintaining a stable market share
    • Sound financial structure (low debt ratio, high liquidity)

  • Negative Factors

    • Drug price reduction policies and government regulations
    • Volatility of raw material prices (especially glucose)
    • Foreign exchange risk
    • Lack of R&D investment and new business development

4. What’s Next? – Continuous Monitoring of Market Conditions and Fundamentals

Fidelity’s stake change may cause short-term stock price fluctuations, but it is not expected to significantly impact Daehan New Pharm’s mid- to long-term outlook. However, external factors such as drug price cuts, raw material price fluctuations, and exchange rate fluctuations, as well as internal factors such as R&D investment and new business development, should be continuously monitored.

5. What Should Investors Do? – Continuous Monitoring and Long-Term Perspective

Rather than reacting to short-term stock price fluctuations, it is advisable to continuously monitor Daehan New Pharm’s fundamentals and market conditions and consider investments from a long-term perspective. Pay particular attention to future announcements regarding R&D investment plans and new business ventures.